{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:33:06Z","timestamp":1792895586466,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jaccao.2019.08.006","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T13:58:06Z","timestamp":1569333486000},"page":"54-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy"],"prefix":"10.1016","volume":"1","author":[{"given":"Muthiah","family":"Vaduganathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer A.","family":"Hirji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navkaranbir","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad G.","family":"Zaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Haykowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-1118","authenticated-orcid":false,"given":"Anju","family":"Nohria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2019.08.006_bib1","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11897-017-0353-9","article-title":"Prevention of chemotherapy induced cardiomyopathy","volume":"14","author":"Payne","year":"2017","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jaccao.2019.08.006_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002843","article-title":"Cancer therapy-related cardiac dysfunction and heart failure: part 2: prevention, treatment, guidelines, and future directions","volume":"9","author":"Hamo","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jaccao.2019.08.006_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jaccao.2019.08.006_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12032-016-0801-5","article-title":"Cancer treatment-related cardiac toxicity: prevention, assessment and management","volume":"33","author":"Fanous","year":"2016","journal-title":"Med Oncol"},{"key":"10.1016\/j.jaccao.2019.08.006_bib5","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2019.08.006_bib6","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2019.08.006_bib7","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archinternmed.2010.233","article-title":"Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study","volume":"170","author":"van der Pal","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaccao.2019.08.006_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-007-9663-z","article-title":"Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials","volume":"109","author":"Bria","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaccao.2019.08.006_bib9","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY Trial","volume":"71","author":"Avila","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2019.08.006_bib10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaccao.2019.08.006_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jaccao.2019.08.006_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jaccao.2019.08.006_bib13","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.cardfail.2005.04.013","article-title":"Elevated NT-ProBNP levels in patients with increased left ventricular filling pressure during exercise despite preserved systolic function","volume":"11","author":"Tschope","year":"2005","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jaccao.2019.08.006_bib14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1586\/14779072.2015.1027686","article-title":"Cardio-oncology part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity","volume":"13","author":"O'Hare","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jaccao.2019.08.006_bib15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jaccao.2019.08.006_bib16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jaccao.2019.08.006_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2019.08.006_bib18","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2019.08.006_bib19","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2019.08.006_bib20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ahj.2010.05.037","article-title":"Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment","volume":"160","author":"Cadeddu","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jaccao.2019.08.006_bib21","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2019.08.006_bib22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","article-title":"Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up","volume":"21","author":"Elitok","year":"2014","journal-title":"Cardiol J"},{"key":"10.1016\/j.jaccao.2019.08.006_bib23","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ajh.21840","article-title":"Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up","volume":"85","author":"Georgakopoulos","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2019.08.006_bib24","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2019.08.006_bib25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12012-016-9365-z","article-title":"Effect of enalapril on preventing anthracycline-induced cardiomyopathy","volume":"17","author":"Janbabai","year":"2017","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.jaccao.2019.08.006_bib26","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4103\/ijmr.IJMR_1323_14","article-title":"Preventive role of carvedilol in adriamycin-induced cardiomyopathy","volume":"144","author":"Jhorawat","year":"2016","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jaccao.2019.08.006_bib27","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaccao.2019.08.006_bib28","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2019.08.006_bib29","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2019.08.006_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.15420\/ahhj.2011.9.2.95","article-title":"Protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma","volume":"9","author":"Salehi","year":"2011","journal-title":"Am Heart Hosp J"},{"key":"10.1016\/j.jaccao.2019.08.006_bib31","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2019.08.006_bib32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FJC.0000000000000470","article-title":"Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity","volume":"69","author":"Nabati","year":"2017","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jaccao.2019.08.006_bib33","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2019.08.006_bib34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2019.08.006_bib35","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2019.08.006_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1456","article-title":"Variability in ejection fraction measured by echocardiography, gated single-photon emission computed tomography, and cardiac magnetic resonance in patients with coronary artery disease and left ventricular dysfunction","volume":"1","author":"Pellikka","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaccao.2019.08.006_bib37","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1093\/eurheartj\/ehw360","article-title":"The evolving field of cardio-oncology: beyond anthracyclines and heart failure","volume":"37","author":"Fradley","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2019.08.006_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ejhf.457","article-title":"Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?","volume":"18","author":"Vaduganathan","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2019.08.006_bib39","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087319300250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087319300250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:51:36Z","timestamp":1762973496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087319300250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2666087319300250"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2019.08.006","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2019.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}